Costly Delays Threaten Japan’s Medical Hubs For Foreign Firms
This article was originally published in PharmAsia News
The effort by Japan's government to attract foreign medical technology companies to a planned series of major hubs faces economic barriers. Many foreign companies are averse to making the investment to locate in the country because of Japan's high costs and its regulations. Massive development efforts already are underway on centers that would specialize in medical and biotechnology research and development, such as one in Kobe that has attracted the interest of 127 medical-related companies. The national government has offered support for such projects by designating cutting-edge medical industrial zones, but delays in other plans to make clinical trials easier to conduct have imposed costly delays on companies. (Click here for more - a subscription may be required
You may also be interested in...
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.